Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9789705 | 0.80 | KMT2A (0.42) | TSHRNPSR1MAPKAPK2PNMTTAAR1 | |
| SCHEMBL24038635 | 0.78 | KDM4E (0.41) | TSHRNPSR1 | |
| SCHEMBL9789723 | 0.78 | TSHR (0.35) | TSHRNPSR1TAAR1 | |
| SCHEMBL10867605 | 0.76 | TAAR1 (0.35) | TSHRNPSR1PNMTTAAR1 | |
| SCHEMBL2844408 | 0.75 | PNMT (0.38) | PNMTTAAR1 | |
| SCHEMBL9207161 | 0.75 | TSHR (0.53) | TSHRNPSR1MAPKAPK2GRIA2 | |
| Hydrochloric Acid SCHEMBL10489402 | 0.73 | TSHR (0.55) | TSHRNPSR1MAPKAPK2GRIA2 | |
| SCHEMBL12760984 | 0.71 | PRCP (0.54) | — | |
| SCHEMBL10653698 | 0.70 | TAAR1 (0.37) | TAAR1 | |
| Hydrochloric Acid SCHEMBL10762375 | 0.69 | TAAR1 (0.35) | TSHRNPSR1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113773251-B | Anilines useful as rory modulators | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-113773251-A | Anilines useful as ROR gamma modulators | 上海辉启生物医药科技有限公司 | 2021-12-10 | — | — | CN | disclosed |
| US-7399770-B2 | Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-15 | — | — | US | disclosed |
| US-20070093482-A1 | THIENO-IMINO ACID DERIVATIVES FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| US-4826855-A | Thieno pyridines and their use as anti-hypertensive agents | BOEHRINGER INGELHEIM KG (DE) | 1989-05-02 | — | — | US | disclosed |
| US-4766129-A | Pyrrolo[2,3-C]pyridines and their use as anti-hypertensive agents | BOEHRINGER INGELHEIM KG (DE) | 1988-08-23 | — | — | US | disclosed |
| US-4683238-A | 2,3,4,9-tetrahydro beta carboline derivatives, useful as antihypertensive agents | BOEHRINGER INGELHEIM KG (DE) | 1987-07-28 | — | — | US | disclosed |
| EP-0174571-A2 | Derivatives of amino acids, process for their preparation and pharmaceutical compositions | BOEHRINGER INGELHEIM KG (DE) | 1986-03-19 | — | — | EP | disclosed |
| US-4555511-A | Thieno [3,2,C]pyridines useful as antihypertensives | BOEHRINGER INGELHEIM KG (DE) | 1985-11-26 | — | — | US | disclosed |
| EP-0116842-A2 | Amino-acids derivatives, process for their preparation and their use | BOEHRINGER INGELHEIM KG (DE) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093482-A1 | THIENO-IMINO ACID DERIVATIVES FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | MMP1, MIF, MMP12 | TSHR 1607/4885NPSR1 3043/4885MAPKAPK2 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.